Key result
The association between drug classes and dementia progression risk depends on the diagnostic measure used, with levodopa reducing MCI-to-AD risk when measured by CDRSOB (OR 0.28) but not clinical diagnosis.
Why the study?
It is unclear whether the CDRSOB scale is consistent with clinical diagnosis when evaluating drug class associations with risk of progression to MCI and dementia.
Does the choice of diagnostic measure (clinical diagnosis vs. CDRSOB) influence the observed associations between drug classes and dementia progression risk?
Cohort (n=39,531)
Yes
Does the choice of diagnostic measure (clinical diagnosis vs. CDRSOB) influence the observed associations between drug classes and dementia progression risk?
Odds Ratio: 0.28
p-value: p=<0.002
The choice of diagnostic outcome measure (clinical diagnosis vs. CDRSOB) significantly alters the observed associations between various drug classes and dementia progression risk, highlighting the need for consensus on diagnostic outcomes in research.
Diagnostic measure choice affects observed drug-dementia associations; leaves open causal effects and supports standardized outcomes in research.
Background Clinical Dementia Rating Sum of Boxes (CDRSOB) scale is known to be highly indicative of cognitive-functional status, but it is unclear whether it is consistent with clinical diagnosis in evaluating drug class associations with risk of progression to mild cognitive impairment (MCI) and dementia. Methods We employed multivariable logistic regression on longitudinal NACC data, to identify drug classes associated with disease progression risk, using clinical diagnosis and CDRSOB as the outcome. Results Anticoagulants, non-steroidal anti-inflammatory drugs, antihypertensives, antidepressants, and Parkinson’s medications were significantly associated with decreased progression to mild cognitive impairment (MCI)/dementia, and antipsychotics, antidiabetics, hypolipidemic drugs, and Alzheimer’s disease (AD) medications were significantly associated with increased progression risk. Associations were however dependant on the diagnostic measure used, e.g., levodopa was associated with reduced MCI-to-AD risk using CDRSOB as the outcome (OR:0.28, FDR p<0.002), but not with clinical diagnosis. Additionally, some associations appear to be gender specific; for instance, antiadrenergic agents had lower MCI-to-Dementia risk only for men (OR:0.67, FDR p<0.001) using CDRSOB. Conclusions Overall, we demonstrate that choice of diagnostic measure can influence the magnitude and significance of risk or protection attributed to drug classes. A consensus must be reached within the research community with respect to the most accurate diagnostic outcome to identify risk and improve reproducibility.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2021) conducted a cohort in Dementia progression (n=39,531). Various drug classes (e.g., levodopa) vs. Absence of the drug of interest was evaluated on Progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) using CDRSOB as the outcome (OR 0.28, p=<0.002). The association between drug classes and dementia progression risk depends on the diagnostic measure used, with levodopa reducing MCI-to-AD risk when measured by CDRSOB (OR 0.28) but not clinical diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: